Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 9/20 | 0.62 |
| ▸ | LOX | P28300 | 3/20 | 0.56 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18223825 | 0.98 | LOXL2 (0.60) | LOXL2LOXLOXL3MAP4K4NOTUM | |
| SCHEMBL14303459 | 0.84 | LOXL2 (0.64) | LOXL2LOXLOXL3IRAK4MAPT | |
| SCHEMBL4128508 | 0.84 | MAP4K4 (0.46) | LOXL2MAP4K4NOTUMMAPTMEN1 | |
| SCHEMBL27802351 | 0.82 | NOS3 (0.47) | LOXL2MAP4K4MAPTMEN1KMT2A | |
| SCHEMBL21376947 | 0.82 | MAP4K4 (0.45) | LOXL2MAP4K4NOTUMMAPTMEN1 | |
| SCHEMBL4772393 | 0.82 | RECQL (0.56) | LOXL2MAP4K4NOTUMMAPTMEN1 | |
| SCHEMBL18049349 | 0.82 | LOXL2 (0.62) | LOXL2LOXLOXL3IRAK4TAAR1 | |
| SCHEMBL5991845 | 0.81 | LOXL2 (0.70) | LOXL2LOXLOXL3NOTUMIRAK4 | |
| SCHEMBL27602586 | 0.81 | LOXL2 (0.56) | LOXL2LOXLOXL3IRAK4TAAR1 | |
| SCHEMBL352525 | 0.80 | LOXL2 (0.61) | LOXL2LOXLOXL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626112-B2 | Heterocyclic sulfonamide derivative and medicine comprising same | EA PHARMA CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160332999-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME | EA PHARMA CO., LTD. (JP) | 2016-11-17 | — | — | US | disclosed |
| US-20160332999-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME | EA PHARMA CO., LTD. (JP) | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332999-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME | TRPA1, TRPV1, TRPV2 | LOXL2 2699/4885LOX 3462/4885LOXL3 2985/4885 |
| US-10626112-B2 | Heterocyclic sulfonamide derivative and medicine comprising same | TRPA1, TRPV1, TRPV2 | LOXL2 2699/4885LOX 3462/4885LOXL3 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.